Nektar Therapeutics (NKTR)
USD 0.49
(-10.6%)
USD 0.49
(-10.6%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 190.9 Million USD | -38.55% |
| 2022 | 310.65 Million USD | -40.61% |
| 2021 | 523.11 Million USD | 1.9% |
| 2020 | 513.36 Million USD | -3.74% |
| 2019 | 533.27 Million USD | 10.87% |
| 2018 | 480.97 Million USD | 49.92% |
| 2017 | 320.82 Million USD | 29.33% |
| 2016 | 248.07 Million USD | 9.74% |
| 2015 | 226.05 Million USD | 19.82% |
| 2014 | 188.65 Million USD | -18.17% |
| 2013 | 230.54 Million USD | 21.15% |
| 2012 | 190.28 Million USD | 9.66% |
| 2011 | 173.52 Million USD | 16.42% |
| 2010 | 149.05 Million USD | 9.5% |
| 2009 | 136.11 Million USD | -1.22% |
| 2008 | 137.8 Million USD | -14.76% |
| 2007 | 161.65 Million USD | -37.55% |
| 2006 | 258.85 Million USD | -2.34% |
| 2005 | 265.05 Million USD | 57.38% |
| 2004 | 168.41 Million USD | 6.75% |
| 2003 | 157.76 Million USD | -16.04% |
| 2002 | 187.9 Million USD | 2.12% |
| 2001 | 184 Million USD | 59.34% |
| 2000 | 115.47 Million USD | 60.49% |
| 1999 | 71.95 Million USD | 64.33% |
| 1998 | 43.78 Million USD | 46.08% |
| 1997 | 29.97 Million USD | 52.92% |
| 1996 | 19.6 Million USD | 47.37% |
| 1995 | 13.3 Million USD | 68.35% |
| 1994 | 7.9 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 50.23 Million USD | 5.63% |
| 2024 Q1 | 47.55 Million USD | 0.62% |
| 2023 Q4 | 47.26 Million USD | 4.52% |
| 2023 Q3 | 45.21 Million USD | -4.91% |
| 2023 Q2 | 47.55 Million USD | -7.76% |
| 2023 FY | 190.9 Million USD | -38.55% |
| 2023 Q1 | 51.55 Million USD | -9.05% |
| 2022 FY | 310.65 Million USD | -40.61% |
| 2022 Q4 | 56.67 Million USD | 0.99% |
| 2022 Q3 | 56.12 Million USD | -11.28% |
| 2022 Q2 | 63.26 Million USD | -53.0% |
| 2022 Q1 | 134.59 Million USD | 2.15% |
| 2021 FY | 523.11 Million USD | 1.9% |
| 2021 Q2 | 130.86 Million USD | 2.82% |
| 2021 Q3 | 133.2 Million USD | 1.79% |
| 2021 Q4 | 131.75 Million USD | -1.09% |
| 2021 Q1 | 127.28 Million USD | -1.98% |
| 2020 Q1 | 135.2 Million USD | -1.68% |
| 2020 Q3 | 127.51 Million USD | 5.57% |
| 2020 Q2 | 120.78 Million USD | -10.67% |
| 2020 Q4 | 129.86 Million USD | 1.84% |
| 2020 FY | 513.36 Million USD | -3.74% |
| 2019 Q1 | 143.46 Million USD | 8.15% |
| 2019 Q2 | 129.26 Million USD | -9.9% |
| 2019 Q3 | 123.03 Million USD | -4.82% |
| 2019 Q4 | 137.51 Million USD | 11.77% |
| 2019 FY | 533.27 Million USD | 10.87% |
| 2018 Q1 | 118.11 Million USD | 25.96% |
| 2018 Q3 | 121.61 Million USD | 11.99% |
| 2018 Q2 | 108.59 Million USD | -8.06% |
| 2018 Q4 | 132.66 Million USD | 9.08% |
| 2018 FY | 480.97 Million USD | 49.92% |
| 2017 Q1 | 73.03 Million USD | 15.94% |
| 2017 Q3 | 77.76 Million USD | 1.98% |
| 2017 Q4 | 93.76 Million USD | 20.57% |
| 2017 FY | 320.82 Million USD | 29.33% |
| 2017 Q2 | 76.25 Million USD | 4.41% |
| 2016 Q1 | 59.49 Million USD | -1.45% |
| 2016 Q3 | 62.2 Million USD | -1.86% |
| 2016 Q4 | 62.99 Million USD | 1.27% |
| 2016 FY | 248.07 Million USD | 9.74% |
| 2016 Q2 | 63.38 Million USD | 6.54% |
| 2015 Q4 | 60.37 Million USD | 14.4% |
| 2015 Q2 | 55.59 Million USD | -3.0% |
| 2015 FY | 226.05 Million USD | 19.82% |
| 2015 Q3 | 52.77 Million USD | -5.08% |
| 2015 Q1 | 57.31 Million USD | 12.95% |
| 2014 Q1 | 48.26 Million USD | -16.9% |
| 2014 FY | 188.65 Million USD | -18.17% |
| 2014 Q2 | 46.32 Million USD | -4.03% |
| 2014 Q3 | 43.33 Million USD | -6.46% |
| 2014 Q4 | 50.74 Million USD | 17.1% |
| 2013 Q4 | 58.08 Million USD | 6.46% |
| 2013 Q2 | 61.45 Million USD | 8.3% |
| 2013 FY | 230.54 Million USD | 21.15% |
| 2013 Q1 | 56.74 Million USD | -0.86% |
| 2013 Q3 | 54.55 Million USD | -11.23% |
| 2012 Q1 | 45.49 Million USD | 1.56% |
| 2012 FY | 190.28 Million USD | 9.66% |
| 2012 Q4 | 57.23 Million USD | 29.84% |
| 2012 Q3 | 44.08 Million USD | 1.41% |
| 2012 Q2 | 43.46 Million USD | -4.46% |
| 2011 Q3 | 43.36 Million USD | -0.2% |
| 2011 Q2 | 43.45 Million USD | 3.7% |
| 2011 Q4 | 44.8 Million USD | 3.3% |
| 2011 FY | 173.52 Million USD | 16.42% |
| 2011 Q1 | 41.9 Million USD | -2.64% |
| 2010 Q2 | 35.8 Million USD | 10.86% |
| 2010 FY | 149.05 Million USD | 9.5% |
| 2010 Q4 | 43.04 Million USD | 13.55% |
| 2010 Q3 | 37.9 Million USD | 5.86% |
| 2010 Q1 | 32.29 Million USD | -6.59% |
| 2009 Q3 | 33.39 Million USD | 0.46% |
| 2009 Q1 | 34.91 Million USD | 487.93% |
| 2009 FY | 136.11 Million USD | -1.22% |
| 2009 Q4 | 34.57 Million USD | 3.55% |
| 2009 Q2 | 33.23 Million USD | -4.79% |
| 2008 Q1 | 49.31 Million USD | 1035.34% |
| 2008 Q3 | 50.65 Million USD | 8.16% |
| 2008 Q4 | -8.99 Million USD | -117.77% |
| 2008 FY | 137.8 Million USD | -14.76% |
| 2008 Q2 | 46.82 Million USD | -5.05% |
| 2007 Q1 | 54.46 Million USD | -20.98% |
| 2007 Q3 | 48.43 Million USD | -10.99% |
| 2007 FY | 161.65 Million USD | -37.55% |
| 2007 Q2 | 54.41 Million USD | -0.09% |
| 2007 Q4 | 4.34 Million USD | -91.03% |
| 2006 FY | 258.85 Million USD | -2.34% |
| 2006 Q4 | 68.92 Million USD | 37.48% |
| 2006 Q3 | 50.13 Million USD | -42.15% |
| 2006 Q2 | 86.66 Million USD | 63.09% |
| 2006 Q1 | 53.13 Million USD | -56.66% |
| 2005 Q1 | 47.33 Million USD | 10.14% |
| 2005 Q2 | 46.9 Million USD | -0.91% |
| 2005 Q3 | 50.52 Million USD | 7.72% |
| 2005 Q4 | 122.59 Million USD | 142.67% |
| 2005 FY | 265.05 Million USD | 57.38% |
| 2004 Q2 | 42.91 Million USD | 8.85% |
| 2004 Q3 | 43.1 Million USD | 0.45% |
| 2004 Q4 | 42.97 Million USD | -0.31% |
| 2004 FY | 168.41 Million USD | 6.75% |
| 2004 Q1 | 39.42 Million USD | -7.73% |
| 2003 Q3 | 37.94 Million USD | -1.8% |
| 2003 FY | 157.76 Million USD | -16.04% |
| 2003 Q4 | 42.72 Million USD | 12.59% |
| 2003 Q2 | 38.64 Million USD | 0.51% |
| 2003 Q1 | 38.44 Million USD | -23.65% |
| 2002 Q3 | 45.86 Million USD | 6.03% |
| 2002 Q2 | 43.25 Million USD | -10.7% |
| 2002 FY | 187.9 Million USD | 2.12% |
| 2002 Q1 | 48.43 Million USD | -11.59% |
| 2002 Q4 | 50.35 Million USD | 9.8% |
| 2001 Q4 | 54.78 Million USD | 11.99% |
| 2001 Q3 | 48.91 Million USD | 13.93% |
| 2001 FY | 184 Million USD | 59.34% |
| 2001 Q2 | 42.93 Million USD | 14.9% |
| 2001 Q1 | 37.36 Million USD | 20.61% |
| 2000 Q4 | 30.98 Million USD | 3.28% |
| 2000 Q2 | 29.09 Million USD | 14.51% |
| 2000 Q1 | 25.4 Million USD | 9.67% |
| 2000 FY | 115.47 Million USD | 60.49% |
| 2000 Q3 | 29.99 Million USD | 3.12% |
| 1999 FY | 71.95 Million USD | 64.33% |
| 1999 Q2 | 16.54 Million USD | 18.35% |
| 1999 Q1 | 13.98 Million USD | 5.8% |
| 1999 Q4 | 23.16 Million USD | 26.86% |
| 1999 Q3 | 18.26 Million USD | 10.37% |
| 1998 FY | 43.78 Million USD | 46.08% |
| 1998 Q4 | 13.21 Million USD | 22.8% |
| 1998 Q3 | 10.76 Million USD | 0.84% |
| 1998 Q2 | 10.67 Million USD | 16.71% |
| 1998 Q1 | 9.14 Million USD | 0.58% |
| 1997 Q1 | 5.92 Million USD | -17.76% |
| 1997 Q4 | 9.08 Million USD | 16.95% |
| 1997 Q3 | 7.77 Million USD | 8.53% |
| 1997 Q2 | 7.16 Million USD | 20.94% |
| 1997 FY | 29.97 Million USD | 52.92% |
| 1996 Q2 | 4.4 Million USD | 22.22% |
| 1996 Q3 | 4.5 Million USD | 2.27% |
| 1996 Q4 | 7.2 Million USD | 60.0% |
| 1996 FY | 19.6 Million USD | 47.37% |
| 1996 Q1 | 3.6 Million USD | -18.18% |
| 1995 Q1 | 2.9 Million USD | -55.38% |
| 1995 Q3 | 3 Million USD | 0.0% |
| 1995 Q4 | 4.4 Million USD | 46.67% |
| 1995 FY | 13.3 Million USD | 68.35% |
| 1995 Q2 | 3 Million USD | 3.45% |
| 1994 Q4 | 6.5 Million USD | 983.33% |
| 1994 FY | 7.9 Million USD | 0.0% |
| 1994 Q2 | 400 Thousand USD | 0.0% |
| 1994 Q1 | 400 Thousand USD | 0.0% |
| 1994 Q3 | 600 Thousand USD | 50.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 30.639% |
| Alkermes plc | 996.24 Million USD | 80.838% |
| Agenus Inc. | 78.18 Million USD | -144.175% |
| Aptorum Group Limited | 10.56 Thousand USD | -1806666.988% |
| Ardelyx, Inc. | 169.93 Million USD | -12.338% |
| Dyadic International, Inc. | 9.15 Million USD | -1985.757% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -757.875% |
| Lantern Pharma Inc. | 17.87 Million USD | -967.835% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -2735.778% |
| Novavax, Inc. | 779.12 Million USD | 75.498% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -135.502% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -132.253% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -883.098% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -544.812% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -259.337% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 49.828% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -685.395% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -404.114% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -520.399% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -125.345% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -993.561% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -13.339% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -483.534% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -19.473% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 89.395% |
| AlloVir, Inc. | 180.93 Million USD | -5.51% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 57.171% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -543.161% |
| Bicycle Therapeutics plc | 216.92 Million USD | 11.995% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -11.053% |
| ChromaDex Corporation | 56.37 Million USD | -238.607% |
| Chimerix, Inc. | 93.38 Million USD | -104.417% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1272.451% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -26.816% |
| CRISPR Therapeutics AG | 463.49 Million USD | 58.812% |
| Precision BioSciences, Inc. | 92.46 Million USD | -106.464% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 24.854% |
| Fortress Biotech, Inc. | 200.19 Million USD | 4.641% |
| Fortress Biotech, Inc. | 200.19 Million USD | 4.641% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -482.981% |
| ImmuCell Corporation | 9.61 Million USD | -1884.983% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -20.967% |
| Immix Biopharma, Inc. | 16.14 Million USD | -1082.713% |
| Incyte Corporation | 1.19 Billion USD | 83.964% |
| Innoviva, Inc. | 132.15 Million USD | -44.455% |
| IO Biotech, Inc. | 91.44 Million USD | -108.767% |
| Jaguar Health, Inc. | 42.01 Million USD | -354.369% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -12.776% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -126.395% |
| ContextLogic Inc. | 387 Million USD | 50.671% |
| MiMedx Group, Inc. | 229.72 Million USD | 16.9% |
| MEI Pharma, Inc. | 34.78 Million USD | -448.808% |
| NextCure, Inc. | 67.63 Million USD | -182.246% |
| Onconetix, Inc. | 34.9 Million USD | -446.884% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -1397.748% |
| Opthea Limited | 191.96 Million USD | 0.554% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -6837.929% |
| Vaxcyte, Inc. | 468.04 Million USD | 59.212% |
| PDS Biotechnology Corporation | 43.04 Million USD | -343.494% |
| Precigen, Inc. | 84.18 Million USD | -126.777% |
| Pharming Group N.V. | 225.49 Million USD | 15.339% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -13.75% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -163.075% |
| PureTech Health plc | 144.59 Million USD | -32.024% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -46.552% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 22.131% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -685.395% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 16.52% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -518.63% |
| Acelyrin, Inc. | 422.06 Million USD | 54.769% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -1480456.848% |
| Summit Therapeutics Inc. | 87.68 Million USD | -117.712% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -415.063% |
| Senti Biosciences, Inc. | 94.7 Million USD | -101.576% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -54.511% |
| Elevation Oncology, Inc. | 45.44 Million USD | -320.075% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -547.81% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -4742.737% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -44.432% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -460.079% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -2158.94% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -5.296% |
| Seer, Inc. | 110.49 Million USD | -72.779% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -170.424% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -104.222% |
| ESSA Pharma Inc. | 32.13 Million USD | -494.082% |
| GlycoMimetics, Inc. | 39.28 Million USD | -385.94% |
| GT Biopharma, Inc. | 13.57 Million USD | -1306.18% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 13.159% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 5.078% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 26.413% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -236.34% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -253.001% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -1821.008% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 52.696% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -908.521% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -276.587% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 26.479% |
| Aptose Biosciences Inc. | 52.35 Million USD | -264.625% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -1224.761% |
| Soligenix, Inc. | 7.79 Million USD | -2348.965% |
| Century Therapeutics, Inc. | 56.07 Million USD | -240.467% |
| Kura Oncology, Inc. | 165.8 Million USD | -15.138% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -66.717% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -2194.783% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -7592.618% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -77.258% |
| Autolus Therapeutics plc | 196.72 Million USD | 2.96% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -125.502% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -63.931% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -884.899% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 40.669% |
| GRI Bio, Inc. | 11.33 Million USD | -1584.934% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -2605.656% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -45.513% |
| IGM Biosciences, Inc. | 265.59 Million USD | 28.121% |
| INmune Bio, Inc. | 29.89 Million USD | -538.557% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -10.634% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -373.537% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1094.685% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -1112.733% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -207.422% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -77.548% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 30.755% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 36.672% |
| Verastem, Inc. | 92.08 Million USD | -107.314% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -964.179% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -2.788% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -57.242% |
| Histogen Inc. | 14.27 Million USD | -1237.605% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -1089.564% |
| Surrozen, Inc. | 18.55 Million USD | -929.127% |
| Organovo Holdings, Inc. | 14.91 Million USD | -1179.94% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -3650.376% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -219.914% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -644.348% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -306.125% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -2401.073% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -7.167% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -294.037% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 22.082% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -1142.326% |
| Apollomics, Inc. | 54.14 Million USD | -252.61% |
| Amarin Corporation plc | 272.35 Million USD | 29.907% |
| Mesoblast Limited | 5.9 Million USD | -3134.548% |
| Turnstone Biologics Corp. | 78.33 Million USD | -143.691% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 21.8% |
| Synaptogenix, Inc. | 8.31 Million USD | -2196.203% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -1208.81% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 24.561% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -472.765% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -2061.68% |
| Exelixis, Inc. | 1.58 Billion USD | 87.969% |
| Better Therapeutics, Inc. | 38.26 Million USD | -398.936% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 17.732% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 77.677% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1516.854% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -2273.853% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -536.492% |
| Gritstone bio, Inc. | 148.37 Million USD | -28.663% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -177.229% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -1066.873% |
| Avid Bioservices, Inc. | 25.99 Million USD | -634.355% |
| Insmed Incorporated | 949.26 Million USD | 79.889% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -1116.734% |
| MediWound Ltd. | 18.86 Million USD | -911.782% |
| OmniAb, Inc. | 83.89 Million USD | -127.55% |
| Alector, Inc. | 248.8 Million USD | 23.271% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 18.525% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -265.358% |
| Zai Lab Limited | 547.47 Million USD | 65.13% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 52.113% |
| Aura Biosciences, Inc. | 84.99 Million USD | -124.616% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 22.754% |
| Immunic, Inc. | 99.22 Million USD | -92.398% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -20.056% |
| Veracyte, Inc. | 357.93 Million USD | 46.665% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 97.883% |
| FibroGen, Inc. | 398.11 Million USD | 52.048% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1243.441% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -2671.552% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -2579.065% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 94.136% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -637.846% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 39.691% |
| TG Therapeutics, Inc. | 198.47 Million USD | 3.815% |
| Galecto, Inc. | 35.62 Million USD | -435.838% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -369.176% |
| Fortrea Holdings Inc. | 457.3 Million USD | 58.254% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -251.713% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -561.067% |
| XBiotech Inc. | 37.51 Million USD | -408.939% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -177.229% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -824.515% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -34.381% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -92.685% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -72.426% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 80.078% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -561.824% |
| Vaxxinity, Inc. | 56.05 Million USD | -240.588% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 55.67% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -755.748% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -72.191% |
| NexImmune, Inc. | 28.16 Million USD | -577.742% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -3351.542% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -966.944% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 93.219% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -649.845% |
| Scopus BioPharma Inc. | 11.71 Million USD | -1529.578% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -50.244% |
| Ainos, Inc. | 12.95 Million USD | -1373.851% |
| Pluri Inc. | 22.48 Million USD | -749.213% |
| Prothena Corporation plc | 282.4 Million USD | 32.401% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 4.559% |
| Celularity Inc. | 215.05 Million USD | 11.232% |
| Rallybio Corporation | 78.93 Million USD | -141.858% |
| Cue Biopharma, Inc. | 19.54 Million USD | -876.886% |
| MeiraGTx Holdings plc | 151.07 Million USD | -26.361% |
| Omeros Corporation | 94.75 Million USD | -101.479% |
| Humacyte, Inc. | 23.49 Million USD | -712.457% |
| Immunocore Holdings plc | 308.04 Million USD | 38.027% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -5531.357% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -119.77% |
| Blueprint Medicines Corporation | 722.86 Million USD | 73.591% |
| CalciMedica, Inc. | 21.81 Million USD | -775.019% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -155.696% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -18.913% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -11.447% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 35.274% |
| Pulmatrix, Inc. | 22.03 Million USD | -766.245% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -452.142% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -114.821% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 65.389% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -163.129% |
| Cytokinetics, Incorporated | 173.61 Million USD | -9.96% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -454.644% |
| Nutriband Inc. | 5.73 Million USD | -3229.298% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -337.72% |
| Vor Biopharma Inc. | 126.03 Million USD | -51.467% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 83.947% |
| Evogene Ltd. | 27.79 Million USD | -586.949% |
| ProKidney Corp. | 151.52 Million USD | -25.99% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -157.368% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -2381.76% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 68.92% |
| CorMedix Inc. | 48.95 Million USD | -289.934% |
| BioLineRx Ltd. | 50.8 Million USD | -275.779% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -26.678% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -401.426% |
| Atai Life Sciences N.V. | 125.78 Million USD | -51.769% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -133.837% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -134.499% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 24.41% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -483.088% |
| MediciNova, Inc. | 10.9 Million USD | -1651.361% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -48.194% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2529.69% |
| GeoVax Labs, Inc. | 6.02 Million USD | -3070.002% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 59.925% |
| Biomea Fusion, Inc. | 126.13 Million USD | -51.348% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 85.448% |
| Mereo BioPharma Group plc | 35.84 Million USD | -432.624% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 0.097% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 16.982% |
| Absci Corporation | 73.66 Million USD | -159.147% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -592.129% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -42.902% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 21.167% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 27.15% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 8.217% |
| Allakos Inc. | 196.05 Million USD | 2.628% |
| Imunon, Inc. | 20.31 Million USD | -839.926% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -68.242% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 48.21% |
| BioAtla, Inc. | 129.68 Million USD | -47.203% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1516.854% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -1104.967% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -124.809% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -357.165% |
| XOMA Corporation | 46.46 Million USD | -310.871% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -71.72% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -34.002% |
| aTyr Pharma, Inc. | 12.97 Million USD | -1370.861% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -84.17% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -10.432% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 25.067% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -410.327% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -2221.062% |
| Akari Therapeutics, Plc | 16.8 Million USD | -1035.922% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -8295.142% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 36.221% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -2737.133% |
| UroGen Pharma Ltd. | 138.88 Million USD | -37.451% |
| Sutro Biopharma, Inc. | 243 Million USD | 21.442% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -2524.233% |
| Orgenesis Inc. | 45.75 Million USD | -317.21% |
| Entera Bio Ltd. | 8.86 Million USD | -2054.661% |
| GH Research PLC | 41.22 Million USD | -363.11% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -642.582% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -129.857% |
| Xencor, Inc. | 306.97 Million USD | 37.812% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -3769.442% |
| Replimune Group, Inc. | 234.77 Million USD | 18.686% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -831.694% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 0.466% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -2737.133% |
| Portage Biotech Inc. | 18.19 Million USD | -948.975% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2529.69% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -81.88% |
| OncoCyte Corporation | 25.63 Million USD | -644.639% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -3031.813% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -1566.248% |
| Purple Biotech Ltd. | -22.46 Million USD | 949.704% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -1058.392% |
| scPharmaceuticals Inc. | 65.17 Million USD | -192.895% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -2158.476% |
| HilleVax, Inc. | 133.34 Million USD | -43.165% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -1756.13% |
| Tharimmune, Inc. | 9.45 Million USD | -1919.022% |
| Genprex, Inc. | 31.06 Million USD | -514.615% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -1.801% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -508.417% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -24854.641% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -3404.789% |
| OKYO Pharma Limited | 8243.57 USD | -2315680.663% |
| Savara Inc. | 15.74 Million USD | -1112.467% |
| Curis, Inc. | 58.35 Million USD | -227.141% |
| Daré Bioscience, Inc. | 33.6 Million USD | -468.005% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -3648.718% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -2458.678% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -606.473% |
| BeiGene, Ltd. | 3.28 Billion USD | 94.191% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -857.421% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 61.725% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -24.244% |
| Erasca, Inc. | 141.52 Million USD | -34.89% |
| bluebird bio, Inc. | 240.23 Million USD | 20.534% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -4117.011% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 89.068% |
| DBV Technologies S.A. | 92.16 Million USD | -107.143% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -4117.011% |
| Moderna, Inc. | 6.39 Billion USD | 97.014% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -348.034% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -1228.853% |
| Molecular Templates, Inc. | 63.09 Million USD | -202.584% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -186.207% |
| Travere Therapeutics, Inc. | 472 Million USD | 59.555% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -33.209% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -207.501% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -339.727% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 8.277% |
| MacroGenics, Inc. | 217.21 Million USD | 12.113% |
| RenovoRx, Inc. | 11.39 Million USD | -1575.176% |
| Adicet Bio, Inc. | 152.03 Million USD | -25.563% |
| Prime Medicine, Inc. | 186.63 Million USD | -2.285% |
| Aditxt, Inc. | 25.95 Million USD | -635.635% |
| Adagene Inc. | 41.83 Million USD | -356.363% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2511.497% |
| Quantum-Si incorporated | 111.65 Million USD | -70.97% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -11.087% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -1209.549% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -432.921% |
| SciSparc Ltd. | 9.01 Million USD | -2018.555% |
| Vericel Corporation | 142.04 Million USD | -34.401% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2105.272% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -726.828% |
| Generation Bio Co. | 144.46 Million USD | -32.143% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -129.921% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -120.799% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 35.445% |
| Invivyd, Inc. | 205.75 Million USD | 7.218% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -164.559% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -1935.538% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -153.678% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -1755.769% |
| 2seventy bio, Inc. | 289.88 Million USD | 34.146% |
| ADMA Biologics, Inc. | 66.58 Million USD | -186.701% |
| Clene Inc. | 41.07 Million USD | -364.79% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -1390.511% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -248.389% |
| GeoVax Labs, Inc. | 6.02 Million USD | -3070.002% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 45.774% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -419.718% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -466.007% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -84.088% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -485.79% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -12.113% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 75.134% |
| Evaxion Biotech A/S | 22.27 Million USD | -757.22% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -40.842% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 18.724% |
| Trevena, Inc. | 38.41 Million USD | -396.975% |
| Surrozen, Inc. | 18.55 Million USD | -929.127% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -138.793% |
| Cingulate Inc. | 22.75 Million USD | -738.795% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 2648.091% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -327.392% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -2218.489% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -86.142% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 74.684% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -207.541% |
| Clearmind Medicine Inc. | 8.74 Million USD | -2083.908% |
| Kronos Bio, Inc. | 128.11 Million USD | -49.006% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -127.071% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -6408.83% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -89.337% |
| Statera Biopharma, Inc. | 28.82 Million USD | -562.179% |
| ImmunityBio, Inc. | 362.87 Million USD | 47.391% |
| Korro Bio, Inc. | 84.53 Million USD | -125.83% |
| Kineta, Inc. | 21.15 Million USD | -802.359% |
| BioVie Inc. | 31.95 Million USD | -497.502% |
| Codexis, Inc. | 66.51 Million USD | -186.994% |
| Celularity Inc. | 215.05 Million USD | 11.232% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 15.761% |
| Celcuity Inc. | 66.23 Million USD | -188.241% |
| Virax Biolabs Group Limited | 6.54 Million USD | -2815.857% |
| Cibus, Inc. | 320.3 Million USD | 40.4% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -343.96% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -464.067% |
| IN8bio, Inc. | 30.33 Million USD | -529.274% |
| Kodiak Sciences Inc. | 277.32 Million USD | 31.162% |
| Annexon, Inc. | 143.72 Million USD | -32.827% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -49.621% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -733.31% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -29728.594% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 75.512% |
| Eyenovia, Inc. | 25.4 Million USD | -651.396% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -36.053% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -3332.273% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -141.243% |
| Arcellx, Inc. | 200.19 Million USD | 4.643% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -315.911% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 11.787% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -1817.274% |
| Moolec Science SA | 52.75 Million USD | -261.897% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -212.249% |
| Geron Corporation | 70.44 Million USD | -171.011% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -310.191% |
| Royalty Pharma plc | 862.4 Million USD | 77.864% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -102.933% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -1946.588% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -743.638% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 8.137% |
| Humacyte, Inc. | 23.49 Million USD | -712.457% |
| Structure Therapeutics Inc. | 102.77 Million USD | -85.748% |
| 89bio, Inc. | 151.2 Million USD | -26.255% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -138.236% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -1212.95% |
| Genelux Corporation | 24.33 Million USD | -684.479% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -462.754% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -10.432% |
| Notable Labs, Ltd. | 14.77 Million USD | -1192.505% |
| Liquidia Corporation | 87.98 Million USD | -116.975% |
| Mustang Bio, Inc. | 48.5 Million USD | -293.606% |
| Immunovant, Inc. | 282.7 Million USD | 32.474% |
| Quantum-Si incorporated | 111.65 Million USD | -70.97% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -746.802% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -797.649% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -87.138% |
| Acasti Pharma Inc. | 11.3 Million USD | -1589.258% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -732.87% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1094.685% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -310.174% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -16725.874% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -1101.706% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -554.742% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -361.297% |
| PepGen Inc. | 84.76 Million USD | -125.212% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -544.268% |
| United Therapeutics Corporation | 885.1 Million USD | 78.431% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -733.747% |
| Solid Biosciences Inc. | 104.31 Million USD | -83.006% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -483.346% |
| Immuneering Corporation | 58.41 Million USD | -226.817% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -3650.376% |
| Silo Pharma, Inc. | 3.92 Million USD | -4767.67% |
| Belite Bio, Inc | 31.66 Million USD | -502.826% |
| XOMA Corporation | 46.46 Million USD | -310.871% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -182.61% |
| Bionomics Limited | 17.89 Billion USD | 98.933% |
| Apogee Therapeutics, Inc. | 93 Million USD | -105.265% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 635.042% |
| uniQure N.V. | 285.08 Million USD | 33.037% |
| Cassava Sciences, Inc. | 105.95 Million USD | -80.17% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2511.497% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 1.701% |
| Forte Biosciences, Inc. | 32.47 Million USD | -487.81% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -2197.613% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -549.44% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -3332.273% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1243.441% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -2047.632% |
| Altimmune, Inc. | 30.55 Million USD | -524.764% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 55.36% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 635.042% |
| Compugen Ltd. | 43.97 Million USD | -334.157% |
| Peak Bio, Inc. | 1249.13 USD | -15282776.882% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -157.559% |
| Benitec Biopharma Inc. | 22.38 Million USD | -752.931% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 21.5% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -568.826% |
| Zura Bio Limited | 62.63 Million USD | -204.772% |
| PolyPid Ltd. | 21.04 Million USD | -807.118% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -1072.911% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -568.826% |
| Instil Bio, Inc. | 85.78 Million USD | -122.537% |
| argenx SE | 1.53 Billion USD | 87.551% |
| Immunome, Inc. | 122.82 Million USD | -55.433% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -293.834% |
| Verona Pharma plc | 67.15 Million USD | -184.288% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -637.504% |
| Shattuck Labs, Inc. | 93.61 Million USD | -103.926% |
| CervoMed Inc. | 14.95 Million USD | -1176.28% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -170.007% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -2134.352% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -274.32% |
| Moolec Science SA | 52.75 Million USD | -261.897% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -1060.615% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -44.018% |
| AnaptysBio, Inc. | 181.56 Million USD | -5.141% |
| Design Therapeutics, Inc. | 78.19 Million USD | -144.153% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -119.325% |
| NeurAxis, Inc. | 8.82 Million USD | -2064.139% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -1416.909% |
| Lumos Pharma, Inc. | 38.66 Million USD | -393.736% |
| Achilles Therapeutics plc | 75.25 Million USD | -153.675% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -637.504% |
| 180 Life Sciences Corp. | 13.47 Million USD | -1316.457% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -620.322% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -6408.83% |
| Nutriband Inc. | 5.73 Million USD | -3229.298% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -72.326% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -243.024% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -275.21% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -188.814% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -252.72% |
| Palisade Bio, Inc. | 13.32 Million USD | -1333.206% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -320.408% |
| Beam Therapeutics Inc. | 554.19 Million USD | 65.553% |
| Neurogene Inc. | 55.58 Million USD | -243.456% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 23.174% |
| AEON Biopharma, Inc. | 48.42 Million USD | -294.191% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -97.397% |
| Sesen Bio, Inc. | 78.38 Million USD | -143.558% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -128.547% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -1416.681% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 57.671% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -117.207% |
| Athira Pharma, Inc. | 125.46 Million USD | -52.155% |
| Vaccinex, Inc. | 23.45 Million USD | -713.912% |
| HCW Biologics Inc. | 21.02 Million USD | -807.872% |
| XOMA Corporation | 46.46 Million USD | -310.871% |
| Arvinas, Inc. | 480 Million USD | 60.229% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -8295.142% |
| Merus N.V. | 200.49 Million USD | 4.784% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -84.706% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -451.424% |
| Rezolute, Inc. | 70.38 Million USD | -171.219% |
| Clene Inc. | 41.07 Million USD | -364.79% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -1065.573% |
| BeyondSpring Inc. | 24.86 Million USD | -667.758% |
| Synlogic, Inc. | 58.53 Million USD | -226.152% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -966.974% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -4149.844% |
| Peak Bio, Inc. | 1249.13 USD | -15282776.882% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -215.824% |
| Krystal Biotech, Inc. | 160.42 Million USD | -18.998% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 29.46% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 45.149% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -8751.486% |
| MannKind Corporation | 125.59 Million USD | -51.996% |
| Ikena Oncology, Inc. | 84.57 Million USD | -125.715% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -1878.885% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -113.059% |
| Gossamer Bio, Inc. | 183.75 Million USD | -3.888% |
| CohBar, Inc. | 12.38 Million USD | -1440.995% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -276.356% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -592.129% |
| Legend Biotech Corporation | 583.14 Million USD | 67.263% |
| Mural Oncology plc | 192.07 Million USD | 0.608% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -184.306% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -1082.408% |
| Disc Medicine, Inc. | 91.12 Million USD | -109.496% |
| Champions Oncology, Inc. | 28.11 Million USD | -579.128% |
| REGENXBIO Inc. | 321.15 Million USD | 40.558% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -3460.803% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -242.39% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -389.989% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -66.936% |
| Vaxart, Inc. | 90.72 Million USD | -110.417% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -2140.643% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -346.097% |
| Cellectis S.A. | 97.32 Million USD | -96.16% |
| Longeveron Inc. | 21.25 Million USD | -798.367% |
| Repare Therapeutics Inc. | 167.35 Million USD | -14.069% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 85.971% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -152.367% |
| Revolution Medicines, Inc. | 498.76 Million USD | 61.725% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -2769.859% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -334.325% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -155.936% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -174.148% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -1626.067% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 96.002% |
| Denali Therapeutics Inc. | 527.23 Million USD | 63.791% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2105.272% |
| Veru Inc. | 101.34 Million USD | -88.364% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -715.581% |
| Cingulate Inc. | 22.75 Million USD | -738.795% |
| Passage Bio, Inc. | 108.38 Million USD | -76.128% |
| Context Therapeutics Inc. | 25.07 Million USD | -661.4% |
| Exicure, Inc. | 14.07 Million USD | -1256.23% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 7.357% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -340.874% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -1980.167% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 24.39% |
| Nuvalent, Inc. | 149.49 Million USD | -27.701% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -2266.497% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -84.18% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -790.032% |
| OmniAb, Inc. | 83.89 Million USD | -127.55% |
| Anew Medical, Inc. | 1.3 Million USD | -14575.352% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -482.661% |
| Lipocine Inc. | 15.08 Million USD | -1165.923% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -178.638% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -150.687% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -373.537% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -66.23% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -752.855% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 71.256% |
| Ocugen, Inc. | 71.56 Million USD | -166.747% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -103.378% |
| Q32 Bio Inc. | 92.68 Million USD | -105.981% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -801.592% |
| Alumis Inc. Common Stock | 158.17 Million USD | -20.692% |
| Equillium, Inc. | 50.6 Million USD | -277.234% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -205.905% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -1272.854% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -911.937% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -306.6% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -76.003% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -1440.444% |
| Dominari Holdings Inc. | 23.83 Million USD | -700.936% |
| Edesa Biotech, Inc. | 9.22 Million USD | -1969.912% |
| vTv Therapeutics Inc. | 11.9 Million USD | -1503.284% |
| Bio-Techne Corporation | 563.03 Million USD | 66.094% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 53.302% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 28.968% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -44.321% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -1224.703% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -16.62% |
| Nkarta, Inc. | 131.65 Million USD | -45.008% |
| BioCardia, Inc. | 12.12 Million USD | -1474.977% |
| Iterum Therapeutics plc | 47.46 Million USD | -302.172% |